Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-04-26
2011-04-26
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S130100, C424S139100, C424S178100
Reexamination Certificate
active
07931900
ABSTRACT:
The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity.
REFERENCES:
patent: 4439196 (1984-03-01), Higuchi
patent: 4447224 (1984-05-01), DeCant, Jr. et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4475196 (1984-10-01), La Zor
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4596556 (1986-06-01), Morrow et al.
patent: 4790824 (1988-12-01), Morrow et al.
patent: 4941880 (1990-07-01), Burns
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5064413 (1991-11-01), McKennon et al.
patent: 5219996 (1993-06-01), Bodner et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5312335 (1994-05-01), McKinnon et al.
patent: 5383851 (1995-01-01), McKinnon, Jr. et al.
patent: 5399163 (1995-03-01), Peterson et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5516637 (1996-05-01), Huang et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5677425 (1997-10-01), Bodner et al.
patent: 5698426 (1997-12-01), Huse
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5738996 (1998-04-01), Hodges et al.
patent: 5750753 (1998-05-01), Kimae et al.
patent: 5780225 (1998-07-01), Wigler et al.
patent: 5807683 (1998-09-01), Brenner
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 6043344 (2000-03-01), Jacobs et al.
patent: 6274711 (2001-08-01), Golstein et al.
patent: 2003/0049255 (2003-03-01), Sims et al.
patent: 0 392 745 (1994-11-01), None
patent: 0 948 544 (2003-05-01), None
patent: 86/01533 (1986-03-01), None
patent: 90/02809 (1990-03-01), None
patent: 91/10737 (1991-07-01), None
patent: 92/01047 (1992-01-01), None
patent: 92/02551 (1992-02-01), None
patent: 92/18619 (1992-10-01), None
patent: 92/22853 (1992-12-01), None
patent: 93/08829 (1993-05-01), None
patent: 93/11236 (1993-06-01), None
patent: 95/15982 (1995-06-01), None
patent: 95/18826 (1995-07-01), None
patent: 95/20401 (1995-08-01), None
patent: 97/04097 (1997-02-01), None
patent: 98/25971 (1998-06-01), None
patent: 99/15549 (1999-04-01), None
patent: 01/46420 (2001-06-01), None
patent: 2004/042009 (2004-05-01), None
patent: 2004/083249 (2004-09-01), None
patent: 2005/000897 (2005-01-01), None
patent: 2005/003169 (2005-01-01), None
patent: 2005/003170 (2005-01-01), None
patent: 2005/003171 (2005-01-01), None
patent: 2007/070750 (2007-06-01), None
patent: 2008/067223 (2008-06-01), None
Kotake et al., IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, The Journal of Clinical Investigation, 103:1345-1352 (1999).
Chabaud et al., “Contribution of Interleukin 17 to Synovium Matrix Destruction in Rheumatoid Arthritis”, Cytokine, 12:1092-1099 (2000).
Aggarwal, S. et al., “Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17”, J. of Biological Chem, 278(3), 2003, 1910-1914.
Ames, R. S. et al., “Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins”, J. Immunol. Methods, vol. 184, 1995, 177-186.
Babcock, J. S. et al., “A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities”, Proc. Natl. Acad. Sci. USA, vol. 93, 1996, 7843-7848.
Baker, D. et al., “Induction of chronic relapsing experimental allergic encephalomyelitis in biozzi mice”, Journal of Neuroimmunology, vol. 28, 1990, 261-270.
Bollard, C. et al., “Adapting a transforming growth factor B-related tumor protection strategy to enhance antitumor immunity”, Blood, 99(9), 2002, 3179-3187.
Brinkman, U. et al., “Phage display of disulfide-stabilized Fv fragments”, J. Immunol. Methods, vol. 182, 1995, 41-50.
Burns, J. A. et al., “Selective reduction of disulfides by tris(2-carboxyethyl)phophine”, J. Org. Chem., vol. 56, 1991, 2648-2650.
Burton, D. R. et al., “Human antibodies for combinatorial libraries”, Advances in Immunology, vol. 57, 1994, 191-280.
Carrell, T. et al., “A novel procedure for the synthesis of libraries containing small organic molecules”, Angew. Chem Inc. Ed. Engl., 33(20), 1994, 2059-2061.
Chapman, A. P., “PEGylated antibodies and antibody fragments for improved therapy: a review”, Advanced Drug Delivery Reviews, vol. 54, 2002, 531-545.
Cho, C. Y. et al., “An unnatural biopolymer”, Science, vol. 261, 1993, 1303-1305.
Chung, D. R. et al., “CD4+ T cells regulate surgical and postinfectious adhesion formation”, J. Exp. Med., 195(11), 2002, 1471-1478.
Cole, S. P. C. et al., “The EBV-hybridoma technique and its application to human lung cancer”, Monclonal Antibodies and Cancer Therapy, 1985, 77-96.
Copray, S. et al., “Deficient p75 low-affinity neurotrophin receptor expression exacerbates experimental allergic encephalomyelitis in C57/BL6 mice”, Journal of Neuroimmunology, vol. 148, 2004, 41-53.
Cull, M. G. et al., “Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor”, Porc. Natl. Acad. Sci. USA, vol. 89, 1992, 1865-1869.
Cwirla, S. E. et al., “Peptides on phage: a vast library of peptides for identifying ligands,” Proc. Natl. Acad. Sci. vol. 87, 1990, 6378-6382.
Devlin, J.J. et al., “Random peptide libraries: a source of specific protein binding molecules,” Science, vol. 249, 1990, 404-406.
Dewitt, S.H. et al., “Diversomers”: an approach to nonpeptide, nonoligomeric chemical diversity, Pro. Natl. Acad. Sci. USA, vol. 90, 1993, 6909-6913.
Dubowchik, G.M. et al., “Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs,” Pharmacology and Therapeutics, vol. 83, 1999, 67-123.
Dumont, F.J. “IL-17 cytokine/receptor families: emerging targets for the modulation of inflammatory responses,” Expert Opin. Ther. Patents, vol. 13(3), 2003, 287-303.
Ellison, D. et al., “Photoreduction of monoclonal antibodies for conjugation and fragmentation,” Biotechniques, vol. 28, 2000, 324-326.
Erb, E. et al., “Recursive deconvolution of combinatorial chemical libraries,” Proc. Natl. Acad. Sci. USA, vol. 91, 1994, 11422-11426.
Felici, F., “Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector,” J. Mol. Biol., vol. 222, 1991, 301-310.
Ferreti, F. et al., “IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger,” Journal of Immunology, vol. 170, 2003, 2106-2112.
Fodor, S.P.A. et al., “Multiplexed biochemical assays with biological chips,” Nature, vol. 364, 1993, 555-556.
Fossiez, F. et al., “Interleukin-17,” Int. Rev. Immunol, vol. 16, 1998, 541-551.
Gallop, M. A. et al., “Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries,” J. Med. Chem., vol. 37(9), 1994, 1233.
Getz, E. B. et al., “A comparison between the sulfhydryl reductants tris(2-carboxyethyl)phosphine and dithiothreitol for use in protein biochemistry,” Analytical Biochemistry, vol. 273, 1999, 73-80.
Goodin, D.S. et al., “Disease modifying therapies in multiple sclerosis; Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the Ms Council for Clinical Practice Guidelines,” American Academy of Neurology, vol. 58(2), 2002, 169-178.
Han, J.C. et al., “A procedure for quantitative determination of tri
Christie Mark Ian
Mead Richard James
Rapecki Stephen Edward
Robinson Martyn Kim
McDonnell Boehnen & Hulbert & Berghoff LLP
Mertz Prema
UCB Pharma S.A.
LandOfFree
Method for the treatment of multiple sclerosis by inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of multiple sclerosis by inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of multiple sclerosis by inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2718676